Loading company…
Massachusetts-based immuno-oncology company developing antibody-drug conjugates and antibody immunotherapies for cancer.
Founded in 2018 by David Steinberg, John L. Flavin and Shaan Gandhi, Pyxis Oncology, Inc. develops antibody-drug conjugates and monoclonal antibody immunotherapies aimed at cancer, drawing on insights into the tumor microenvironment. In March 2021 it raised USD 152 million in Series B financing backed by Arix Bioscience, RTW Investments, Pfizer Ventures, BVF Partners, Leaps by Bayer, Longwood Fund, Agent Capital and Ipsen. The company trades on Nasdaq as PYXO.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in